annual report, page-2

Also this on the CR (controlled release) formulation still in development from John Holaday CEO...p5:

The results of these early trials exceeded our expectations. MOXDUO CR demonstrated superior bioavailability and sustained blood levels for well over 12
hours, especially in the 12 – 24 hour period, when compared directly to OxyContin®,
the largest selling opioid for chronic pain. These outcomes indicate that MOXDUO CR will be effective as a once or twice a day chronic pain drug, as opposed to
OxyContin, which despite labelling for twice daily dosing, is actually prescribed three times a day to almost a third of patients, according to IMS Health.